# Global, regional, and national burden of idiopathic epilepsy in older adults, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12306114</article-id><article-id pub-id-type="pmid">40722097</article-id>
<article-id pub-id-type="publisher-id">4268</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04268-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Global, regional, and national burden of idiopathic epilepsy in older adults, 1990&#x02013;2021: a systematic analysis for the Global Burden of Disease Study 2021</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Xue</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Xiaopan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Yajun</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Wenchang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xiaoling</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Sunfang</given-names></name><address><email>jiang.sunfang@zs-hospital.sh.cn</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ding</surname><given-names>Jing</given-names></name><address><email>ding.jing@zs-hospital.sh.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032x22645</institution-id><institution-id institution-id-type="GRID">grid.413087.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1755 3939</institution-id><institution>Department of Neurology, </institution><institution>Zhongshan Hospital, Fudan University, </institution></institution-wrap>180 Fenglin Road, Shanghai, 200032 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032x22645</institution-id><institution-id institution-id-type="GRID">grid.413087.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1755 3939</institution-id><institution>Department of Health Management Center, </institution><institution>Zhongshan Hospital, Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>School of Public Health, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032x22645</institution-id><institution-id institution-id-type="GRID">grid.413087.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1755 3939</institution-id><institution>Department of General Practice, </institution><institution>Zhongshan Hospital, Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00vpwhm04</institution-id><institution-id institution-id-type="GRID">grid.507732.4</institution-id><institution>CAS Center for Excellence in Brain Science and Intelligence Technology, </institution></institution-wrap>Shanghai, 200032 China </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>443</elocation-id><history><date date-type="received"><day>7</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>7</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Epilepsy among older populations has emerged as a growing global health concern in recent decades. However, comprehensive analyses of epilepsy burden among older adults are limited. This study aimed to assess the global burden of idiopathic epilepsy in the population aged 60 and above from 1990 to 2021 and project trends through 2035.</p></sec><sec><title>Methods</title><p id="Par2">Using data from the Global Burden of Disease (GBD) study 2021, we analyzed epilepsy-related metrics including incidence, prevalence, mortality, and disability-adjusted life years (DALYs) across 204 countries and territories, stratified by age, sex, and Socio-demographic Index (SDI). Data analysis encompassed relative change calculations, as well as average annual percentage change (AAPC). Additionally, we performed a decomposition analysis to determine the contributions of population growth, aging, and epidemiological changes, and used Bayesian age-period-cohort (BAPC) modeling to project future burden through 2035.</p></sec><sec><title>Results</title><p id="Par3">From 1990 to 2021, the global burden of idiopathic epilepsy in older adults increased substantially, with rises in age-standardized incidence (26.64%), prevalence (20.01%), mortality (4.45%), and DALYs (0.32%). Males consistently showed higher burden across metrics. Regional analysis revealed significant disparities, with Western Europe reporting the highest age-standardized incidence rate and Andean Latin America the highest prevalence rate in 2021. Higher SDI regions demonstrated better outcomes in mortality and DALYs, though showing unique increases in age-standardized rates. Population growth emerged as the primary driver of increased burden across regions. Projections through 2035 indicate continuing increases in incidence (AAPC: 1.64%) and prevalence (AAPC: 1.34%) rates, while mortality (AAPC: -1.29%) and DALY (AAPC: -0.12%) rates are expected to decline.</p></sec><sec><title>Conclusions</title><p id="Par4">The global burden of idiopathic epilepsy in older adults has increased significantly, with notable disparities across regions and socioeconomic levels.&#x000a0;While projected declines in mortality and DALY rates suggest improving healthcare outcomes, rising incidence and prevalence rates highlight the need for enhanced prevention strategies and specialized geriatric epilepsy care, particularly in resource-limited settings.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04268-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Burden of disease</kwd><kwd>Elderly</kwd><kwd>Epilepsy</kwd><kwd>Epidemiology</kwd><kwd>Trends</kwd></kwd-group><funding-group><award-group><funding-source><institution>Shanghai Public Health System Construction Three-year Action Plan Key Discipline Construction Program</institution></funding-source><award-id>GWVI-11.1-44; to author SJ</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Shanghai Action Plan for Science, Technology and Innovation</institution></funding-source><award-id>23JS1401000</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>National Key R&#x00026;D Program of China</institution></funding-source><award-id>2022YFC2503802</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par17">Epilepsy is a chronic brain disease characterized by a lasting predisposition to generate spontaneous epileptic seizures, with significant neurobiological, cognitive, and psychosocial consequences [<xref ref-type="bibr" rid="CR1">1</xref>]. As one of the most prevalent neurological disorders, epilepsy affects over 70 million people globally across diverse demographics and geographies [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite its prevalence, epilepsy remains stigmatized in many regions worldwide, preventing numerous patients from accessing essential treatment. Healthcare providers in low-income countries face substantial challenges in diagnosis and treatment due to limited resources and cultural barriers [<xref ref-type="bibr" rid="CR3">3</xref>]. In fact, up to 70% of epilepsy patients can achieve effective control through appropriate treatment [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], highlighting the importance of prioritizing epilepsy in global healthcare agendas.</p><p id="Par18">The Global Burden of Disease (GBD) study provides standardized health loss estimates across diseases, offering vital insights for health planning. Key metrics assessed include disability-adjusted life years (DALYs), incidence, prevalence, mortality and associated risk factors.&#x000a0;Although global age-standardized DALY rates for epilepsy decreased by nearly 15% from 1990 to 2021, it remains the seventh most burdensome neurological condition [<xref ref-type="bibr" rid="CR6">6</xref>]. The burden of epilepsy exhibits significant disparities across sex and geographical regions, with men experiencing higher rates across multiple metrics [<xref ref-type="bibr" rid="CR7">7</xref>] and approximately 80% of patients residing in low- and middle-income countries where incidence rates substantially exceed those in high-income nations [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par19">Global population aging presents a significant medical and demographic challenge. Predictions indicate that by 2050, there will be more older people aged 60 or above than teenagers aged 10&#x02013;24 [<xref ref-type="bibr" rid="CR9">9</xref>]. It is particularly critical that the incidence of epilepsy has a bimodal distribution with the highest risk in infants and older age groups [<xref ref-type="bibr" rid="CR2">2</xref>]. Moreover, epilepsy burden in the elderly population is likely underestimated due to atypical presentations and predominantly focal seizures [<xref ref-type="bibr" rid="CR10">10</xref>]. Elderly individuals with epilepsy face unique challenges, including increased vulnerability to seizure complications, complex medication interactions, altered drug metabolism, limited specialized care access, consequently imposing a significant socioeconomic burden on healthcare systems [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. While previous GBD studies have primarily examined general populations,&#x000a0;this study specifically examines epilepsy epidemiology in older adults using GBD 1990&#x02013;2021 data from 204 countries to provide age-, sex-, and socioeconomic-stratified analysis, complemented by Bayesian age-period-cohort (BAPC) modeling to project burden trends through 2035.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data sources</title><p id="Par20">The GBD Study is a systematic and comprehensive study of diseases worldwide. This is a publicly available dataset that is free to use, as the Institutional Review Board of the University of Washington has waived the informed consent requirement for accessing GBD data [<xref ref-type="bibr" rid="CR13">13</xref>]. We utilized data from GBD 2021 (<ext-link ext-link-type="uri" xlink:href="https://ghdx.healthdata.org/gbd-results-tool">https://ghdx.healthdata.org/gbd-results-tool</ext-link>), which reported the latest epidemiological data and improved standardized methods to comprehensively assess health loss linked to 371 diseases, injuries, and impairments, as well as 88 risk factors in 204 countries and territories [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The details of methodology of the GBD Study 2021 used in this study have been described elsewhere [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec4"><title>Epilepsy definitions</title><p id="Par21">Given that the GBD study exclusively provided comprehensive burden indicators for idiopathic epilepsy, our study primarily focused on this form of epilepsy. Idiopathic epilepsy was defined by the GBD study according to the 1985 International League Against Epilepsy (ILAE) proposal [<xref ref-type="bibr" rid="CR16">16</xref>], and only included those of genetic or unknown causes.</p></sec><sec id="Sec5"><title>Target population</title><p id="Par22">We defined the older population as individuals aged&#x02009;&#x02265;&#x02009;60&#x000a0;years, consistent with age stratification criteria reported in both previous GBD studies [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and epilepsy clinical trials [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Thus, this study included elderly patients diagnosed with idiopathic epilepsy from all regions of GBD 2021.</p></sec><sec id="Sec6"><title>Study measures and classifications</title><p id="Par23">In this study, we analyzed four primary metrics: incidence, prevalence, mortality, and DALYs associated with epilepsy at global, regional, and national levels. The socio-demographic index (SDI) was used as a composite measure of development status, integrating total fertility rate, educational attainment, and lag-distributed income. This index ranges from 0 to 1 and demonstrates a strong correlation with health outcomes, where higher values reflect greater socioeconomic development [<xref ref-type="bibr" rid="CR22">22</xref>]. Based on 2021 SDI values, countries were stratified into five development categories: high SDI (&#x0003e;&#x02009;0.81), high-middle SDI (0.70&#x02013;0.81), middle SDI (0.61&#x02013;0.70), low-middle SDI (0.46&#x02013;0.60), and low SDI (&#x0003c;&#x02009;0.46). Age-specific analysis covered eight groups within the older population (60&#x02013;64, 65&#x02013;69, 70&#x02013;74, 75&#x02013;79, 80&#x02013;84, 85&#x02013;89, 90&#x02013;94, and 95&#x02009;+&#x02009;years).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par24">We analyzed key measures using both absolute numbers and age-standardized rates (ASRs) (per 100,000 population) with 95% uncertainty intervals (UIs). Age standardization used the 2021 GBD world population standard age structure. The data were stratified across age, sex, year, 21 GBD regions and 204 nations and territories. To determine the 95% UIs, we generated 500 iterations from the model's posterior distribution for each estimate, taking the 12.5th and 487.5th ordered values [<xref ref-type="bibr" rid="CR6">6</xref>]. When evaluating temporal changes, we considered a percentage change statistically significant if its 95% UIs excluded zero. To quantify temporal changes between 1990 and 2021, we calculated the relative percentage change for both absolute case numbers and ASRs per 100,000 population [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par25">For temporal trend analysis, we calculated the average annual percentage change (AAPC) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. For AAPC calculation, we fit the natural logarithm of ASR against calendar year: ln (ASR)&#x02009;=&#x02009;&#x003b1;&#x02009;+&#x02009;&#x003b2;&#x02009;&#x000d7;&#x02009;(calendar year)&#x02009;+&#x02009;&#x003b5;, with AAPC derived as 100&#x02009;&#x000d7;&#x02009;(exp(&#x003b2;)&#x000a0;&#x02212;&#x000a0;1) and reported with its 95% confidence interval (CI).</p><p id="Par26">We examined relationships between epilepsy burden and SDI using smoothing splines models and Locally Weighted Scatterplot Smoothing (LOESS). Spearman's correlation analysis was used to estimate the &#x003c1; (rho) values and p values for the association of age-standardized rate with SDI [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par27">To understand the drivers of change in epilepsy indicators between 1990 and 2021, we performed decomposition analyses using Das Gupta's method [<xref ref-type="bibr" rid="CR26">26</xref>], quantifying contributions from age distribution, population magnitude, and epidemiology of idiopathic epilepsy. For future projections (2022&#x02013;2035), we implemented a BAPC model with integrated nested Laplace approximations, which provides superior coverage for predicting disease rates and future burden compared to alternative models [<xref ref-type="bibr" rid="CR27">27</xref>]. We conducted all analyses using the BAPC package in R software, adhering to validated methodological protocols from previous studies [<xref ref-type="bibr" rid="CR27">27</xref>]. All analyses were performed using R software (version 4.3.2), with statistical significance defined as a two-sided <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Global trends</title><p id="Par28">Between 1990 and 2021, the global incidence of epilepsy in the population aged 60&#x000a0;years and above increased by 191.45% (from 116,560.47 to 339,711.09 cases), while age-standardized incidence rate (ASIR) increased by 26.64% (from 25.04 to 31.71 per 100,000). The absolute prevalence increased by 175.17%, with age-standardized prevalence rate (ASPR) rising 20.01%. Despite a 141.65% increase in absolute mortality, the age-standardized mortality rate (ASMR) increased only 4.45%. DALYs demonstrated a substantial increase of 126.33% in absolute numbers, while age-standardized DALY rate (ASDR) showed minimal change (+&#x02009;0.32%) (Tables <xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>, and <xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Numbers and ASRs per 100,000 cases of incidence of elderly epilepsy among older population in 1990 and 2021, along with the relative changes and AAPC in ASRs per 100,000 cases from 1990 to 2021, categorized by global, SDI, and GBD regions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Number (95%UI) In 1990</th><th align="left">Number (95%UI) In 2021</th><th align="left">Relative change of numbers from 1990 to 2021 (%)</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 1990</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 2021</th><th align="left">Relative change of age-standardized rate from 1990 to 2021 (%)</th><th align="left">AAPC, 95%CI (%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Global</td><td align="left">116560.47 (67299.69, 180331.45)</td><td align="left">339711.09 (193524.66, 521688.92)</td><td align="left">191.45</td><td align="left">25.04 (14.35, 39.06)</td><td align="left">31.71 (18.02, 48.84)</td><td align="left">26.64</td><td align="left">0.78 (0.75, 0.81)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="9">SDI Regions</td></tr><tr><td align="left">&#x02003;High SDI</td><td align="left">40517.08 (22794.01, 63960.14)</td><td align="left">113255.79 (61791.67, 175864.78)</td><td align="left">179.53</td><td align="left">28.35 (15.87, 45.01)</td><td align="left">39.97 (21.93, 61.87)</td><td align="left">40.99</td><td align="left">1.12 (1.08, 1.16)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-middle SDI</td><td align="left">23842.72 (13096.57, 37761.86)</td><td align="left">62060.78 (33320.70, 98618.03)</td><td align="left">160.29</td><td align="left">19.44 (10.60, 31.06)</td><td align="left">24.48 (13.11, 39.09)</td><td align="left">25.93</td><td align="left">0.78 (0.70, 0.85)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Middle SDI</td><td align="left">26749.13 (14779.27, 42869.01)</td><td align="left">94538.98 (52088.85, 150023.72)</td><td align="left">253.43</td><td align="left">23.70 (12.95, 38.46)</td><td align="left">29.51 (16.19, 47.20)</td><td align="left">24.51</td><td align="left">0.76 (0.71, 0.81)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low-middle SDI</td><td align="left">17915.14 (9219.76, 30213.72)</td><td align="left">51768.25 (29179.92, 81806.68)</td><td align="left">188.96</td><td align="left">27.32 (13.97, 46.60)</td><td align="left">31.86 (17.90, 50.79)</td><td align="left">16.62</td><td align="left">0.48 (0.46, 0.50)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low SDI</td><td align="left">7416.63 (3578.57, 12863.37)</td><td align="left">17823.83 (10196.76, 28364.84)</td><td align="left">140.32</td><td align="left">31.97 (15.43, 56.47)</td><td align="left">34.81 (19.75, 55.96)</td><td align="left">8.88</td><td align="left">0.27 (0.26, 0.28)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Asia</td><td align="left">1142.41 (585.78, 1950.89)</td><td align="left">2604.46 (1329.76, 4308.78)</td><td align="left">127.98</td><td align="left">19.50 (9.90, 33.42)</td><td align="left">25.06 (12.60, 41.72)</td><td align="left">28.51</td><td align="left">0.82 (0.81, 0.83)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Europe</td><td align="left">3247.82 (1703.40, 5263.87)</td><td align="left">5650.41 (2918.12, 9078.61)</td><td align="left">73.98</td><td align="left">16.27 (8.47, 26.49)</td><td align="left">19.13 (9.89, 30.77)</td><td align="left">17.58</td><td align="left">0.52 (0.51, 0.54)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Eastern Europe</td><td align="left">5390.26 (2819.97, 8873.97)</td><td align="left">8238.22 (4398.33, 13372.92)</td><td align="left">52.84</td><td align="left">14.55 (7.54, 24.11)</td><td align="left">17.02 (9.06, 27.70)</td><td align="left">16.98</td><td align="left">0.48 (0.47, 0.50)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Australasia</td><td align="left">819.98 (278.16, 1508.91)</td><td align="left">2084.91 (683.87, 3911.33)</td><td align="left">154.26</td><td align="left">26.98 (9.14, 49.90)</td><td align="left">29.13 (9.59, 54.64)</td><td align="left">7.97</td><td align="left">0.24 (0.22, 0.25)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-income Asia Pacific</td><td align="left">6024.82 (3167.56, 9811.38)</td><td align="left">20646.39 (10189.49, 34733.38)</td><td align="left">242.69</td><td align="left">24.52 (12.80, 40.31)</td><td align="left">32.61 (16.20, 54.13)</td><td align="left">32.99</td><td align="left">0.92 (0.89, 0.95)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-income North America</td><td align="left">9736.79 (5163.47, 16051.78)</td><td align="left">30787.92 (15394.74, 50982.32)</td><td align="left">216.20</td><td align="left">20.97 (11.08, 34.71)</td><td align="left">34.49 (17.31, 56.98)</td><td align="left">64.47</td><td align="left">1.63 (1.52, 1.75)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Latin America</td><td align="left">1155.42 (467.45, 2099.44)</td><td align="left">2988.65 (1298.67, 5259.23)</td><td align="left">158.66</td><td align="left">20.02 (8.08, 36.51)</td><td align="left">26.49 (11.51, 46.62)</td><td align="left">32.32</td><td align="left">0.91 (0.91, 0.92)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Europe</td><td align="left">26362.41 (14712.51, 41727.74)</td><td align="left">63909.19 (34022.59, 97360.41)</td><td align="left">142.43</td><td align="left">34.68 (19.24, 55.24)</td><td align="left">50.85 (27.19, 77.66)</td><td align="left">46.63</td><td align="left">1.25 (1.24, 1.27)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Andean Latin America</td><td align="left">913.35 (373.08, 1661.62)</td><td align="left">3239.88 (1477.96, 5613.37)</td><td align="left">254.72</td><td align="left">39.04 (15.89, 71.41)</td><td align="left">45.25 (20.64, 78.40)</td><td align="left">15.91</td><td align="left">0.45 (0.42, 0.48)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Caribbean</td><td align="left">879.62 (443.45, 1442.67)</td><td align="left">2012.26 (1024.89, 3382.44)</td><td align="left">128.76</td><td align="left">28.20 (14.15, 46.56)</td><td align="left">29.76 (15.22, 49.81)</td><td align="left">5.53</td><td align="left">0.18 (0.17, 0.18)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Latin America</td><td align="left">4119.40 (2269.21, 6658.30)</td><td align="left">13994.00 (7799.41, 22437.29)</td><td align="left">239.71</td><td align="left">43.58 (23.84, 70.83)</td><td align="left">45.40 (25.29, 72.74)</td><td align="left">4.18</td><td align="left">0.13 (0.12, 0.14)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Tropical Latin America</td><td align="left">3630.10 (1813.75, 6013.38)</td><td align="left">12998.05 (6476.99, 21904.08)</td><td align="left">258.06</td><td align="left">34.35 (16.99, 57.77)</td><td align="left">40.54 (20.19, 68.31)</td><td align="left">18.02</td><td align="left">0.54 (0.53, 0.55)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;North Africa and Middle East</td><td align="left">3863.60 (1995.64, 6391.17)</td><td align="left">13928.55 (7275.91, 22447.46)</td><td align="left">260.51</td><td align="left">21.41 (11.00, 35.78)</td><td align="left">28.43 (14.78, 46.21)</td><td align="left">32.79</td><td align="left">0.91 (0.87, 0.93)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;South Asia</td><td align="left">17551.65 (8929.21, 29956.15)</td><td align="left">55491.35 (31393.06, 86735.86)</td><td align="left">216.16</td><td align="left">29.20 (14.78, 50.47)</td><td align="left">33.19 (18.65, 52.32)</td><td align="left">13.66</td><td align="left">0.39 (0.36, 0.42)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;East Asia</td><td align="left">17615.40 (9481.48, 28831.63)</td><td align="left">57907.52 (31323.85, 92955.82)</td><td align="left">228.73</td><td align="left">17.82 (9.45, 29.55)</td><td align="left">21.37 (11.49, 34.63)</td><td align="left">19.92</td><td align="left">0.76 (0.57, 0.99)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Oceania</td><td align="left">61.78 (25.04, 116.19)</td><td align="left">156.37 (69.00, 280.04)</td><td align="left">153.11</td><td align="left">20.39 (8.36, 38.14)</td><td align="left">20.60 (9.15, 36.83)</td><td align="left">1.03</td><td align="left">0.03 (0.02, 0.04)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southeast Asia</td><td align="left">5502.30 (3029.18, 9129.34)</td><td align="left">21527.60 (11526.56, 34732.15)</td><td align="left">291.25</td><td align="left">19.86 (10.82, 33.33)</td><td align="left">28.49 (15.09, 46.48)</td><td align="left">43.45</td><td align="left">1.17 (1.15, 1.18)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Sub-Saharan Africa</td><td align="left">1031.66 (313.47, 2005.23)</td><td align="left">2462.25 (958.82, 4451.83)</td><td align="left">138.67</td><td align="left">43.98 (13.52, 85.87)</td><td align="left">44.50 (17.09, 81.15)</td><td align="left">1.18</td><td align="left">0.02 (0.00, 0.04)</td><td align="left">0.088</td></tr><tr><td align="left">&#x02003;Eastern Sub-Saharan Africa</td><td align="left">2741.14 (1354.23, 4749.84)</td><td align="left">6943.45 (3892.13, 11018.31)</td><td align="left">153.31</td><td align="left">37.69 (18.54, 66.07)</td><td align="left">43.04 (23.99, 68.86)</td><td align="left">14.19</td><td align="left">0.44 (0.42, 0.47)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Sub-Saharan Africa</td><td align="left">1220.20 (652.18, 2006.38)</td><td align="left">3037.78 (1622.20, 4927.12)</td><td align="left">148.96</td><td align="left">40.13 (21.21, 66.68)</td><td align="left">47.34 (24.91, 77.92)</td><td align="left">17.97</td><td align="left">0.53 (0.51, 0.54)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Sub-Saharan Africa</td><td align="left">3550.35 (1803.71, 6101.85)</td><td align="left">9101.88 (5124.13, 14314.90)</td><td align="left">156.37</td><td align="left">38.75 (19.48, 68.03)</td><td align="left">46.73 (25.98, 74.58)</td><td align="left">20.59</td><td align="left">0.61 (0.60, 0.62)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Numbers and ASRs per 100,000 cases of prevalence of elderly epilepsy in 1990 and 2021, along with the relative changes and AAPC in ASRs per 100,000 cases from 1990 to 2021, categorized by global, SDI, and GBD regions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Number (95%UI) In 1990</th><th align="left">Number (95%UI) In 2021</th><th align="left">Relative change of numbers from 1990 to 2021 (%)</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 1990</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 2021</th><th align="left">Relative change of age-standardized rate from 1990 to 2021 (%)</th><th align="left">AAPC, 95% CI (%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Global</td><td align="left">1664853.90 (1193617.54, 2289875.25)</td><td align="left">4581228.63 (3199440.84, 6439053.95)</td><td align="left">175.17</td><td align="left">355.35 (254.59, 487.93)</td><td align="left">426.44 (297.71, 598.60)</td><td align="left">20.01</td><td align="left">0.60 (0.58, 0.62)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="9">SDI Regions</td></tr><tr><td align="left">&#x02003;High SDI</td><td align="left">571746.47 (379954.08, 799563.98)</td><td align="left">1485839.69 (948867.76, 2109043.58)</td><td align="left">159.88</td><td align="left">397.30 (263.84, 556.06)</td><td align="left">524.49 (335.21, 747.82)</td><td align="left">32.01</td><td align="left">0.90 (0.87, 0.93)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-middle SDI</td><td align="left">384852.77 (269557.80, 538968.00)</td><td align="left">905293.69 (604880.36, 1301342.61)</td><td align="left">135.23</td><td align="left">313.51 (219.11, 438.12)</td><td align="left">355.68 (237.41, 511.01)</td><td align="left">13.45</td><td align="left">0.44 (0.39, 0.50)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Middle SDI</td><td align="left">378460.78 (253775.82, 536977.89)</td><td align="left">1311793.76 (903472.97, 1865509.11)</td><td align="left">246.61</td><td align="left">336.28 (225.05, 475.60)</td><td align="left">408.84 (281.29, 580.11)</td><td align="left">21.58</td><td align="left">0.66 (0.62, 0.70)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low-middle SDI</td><td align="left">232783.88 (140349.83, 349300.82)</td><td align="left">655829.66 (451060.29, 914146.23)</td><td align="left">181.73</td><td align="left">354.67 (214.02, 531.81)</td><td align="left">400.92 (275.97, 558.63)</td><td align="left">13.04</td><td align="left">0.38 (0.35, 0.40)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low SDI</td><td align="left">94755.81 (51716.08, 148054.30)</td><td align="left">217990.77 (141330.86, 319551.72)</td><td align="left">130.06</td><td align="left">397.60 (216.21, 622.89)</td><td align="left">411.42 (266.48, 599.87)</td><td align="left">3.48</td><td align="left">0.10 (0.08, 0.11)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Asia</td><td align="left">23676.46 (13989.12, 34457.42)</td><td align="left">52130.79 (29480.00, 74907.60)</td><td align="left">120.18</td><td align="left">418.00 (246.76, 609.45)</td><td align="left">528.83 (300.20, 757.40)</td><td align="left">26.51</td><td align="left">0.74 (0.72, 0.76)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Europe</td><td align="left">79374.05 (52471.30, 112986.51)</td><td align="left">138782.26 (90047.40, 195612.99)</td><td align="left">74.85</td><td align="left">403.04 (266.62, 571.90)</td><td align="left">464.01 (300.90, 654.57)</td><td align="left">15.13</td><td align="left">0.45 (0.44, 0.46)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Eastern Europe</td><td align="left">105421.22 (70707.27, 149814.23)</td><td align="left">142421.72 (92439.25, 206422.37)</td><td align="left">35.10</td><td align="left">288.33 (193.09, 409.74)</td><td align="left">296.32 (192.32, 429.44)</td><td align="left">2.77</td><td align="left">0.08 (0.06, 0.09)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Australasia</td><td align="left">11848.83 (4320.50, 19838.49)</td><td align="left">29014.66 (10733.22, 48432.31)</td><td align="left">144.87</td><td align="left">386.16 (140.82, 646.45)</td><td align="left">405.36 (149.80, 677.85)</td><td align="left">4.97</td><td align="left">0.16 (0.15, 0.17)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-income Asia Pacific</td><td align="left">80603.14 (50901.67, 117996.61)</td><td align="left">256571.87 (150681.71, 376300.13)</td><td align="left">218.31</td><td align="left">326.18 (205.96, 477.27)</td><td align="left">401.99 (233.65, 594.36)</td><td align="left">23.24</td><td align="left">0.68 (0.65, 0.71)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-income North America</td><td align="left">144492.97 (95330.22, 206981.29)</td><td align="left">430979.55 (261773.26, 630562.90)</td><td align="left">198.27</td><td align="left">310.57 (204.43, 445.62)</td><td align="left">482.89 (293.70, 706.87)</td><td align="left">55.49</td><td align="left">1.44 (1.35, 1.53)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Latin America</td><td align="left">17974.88 (8606.92, 28665.13)</td><td align="left">44715.03 (22284.84, 70980.67)</td><td align="left">148.76</td><td align="left">309.15 (147.96, 492.70)</td><td align="left">395.64 (197.05, 628.34)</td><td align="left">27.98</td><td align="left">0.80 (0.80, 0.81)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Europe</td><td align="left">349333.19 (220890.19, 495725.70)</td><td align="left">766067.85 (452342.71, 1089030.50)</td><td align="left">119.29</td><td align="left">455.62 (287.85, 647.71)</td><td align="left">606.59 (357.52, 868.56)</td><td align="left">33.14</td><td align="left">0.94 (0.92, 0.95)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Andean Latin America</td><td align="left">16018.42 (7489.06, 25005.96)</td><td align="left">52028.19 (26996.61, 81605.36)</td><td align="left">224.80</td><td align="left">683.24 (318.82, 1067.80)</td><td align="left">726.39 (376.62, 1138.73)</td><td align="left">6.32</td><td align="left">0.17 (0.15, 0.21)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Caribbean</td><td align="left">13797.22 (8296.73, 20166.60)</td><td align="left">30074.44 (18157.03, 43821.63)</td><td align="left">117.97</td><td align="left">437.49 (262.83, 639.35)</td><td align="left">445.74 (269.44, 649.02)</td><td align="left">1.89</td><td align="left">0.07 (0.06, 0.08)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Latin America</td><td align="left">64162.94 (41749.13, 92881.86)</td><td align="left">215640.51 (145732.26, 308675.88)</td><td align="left">236.08</td><td align="left">682.43 (444.23, 985.70)</td><td align="left">703.85 (475.71, 1006.23)</td><td align="left">3.14</td><td align="left">0.10 (0.09, 0.11)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Tropical Latin America</td><td align="left">59313.59 (36732.03, 87134.67)</td><td align="left">192481.81 (117916.26, 285601.63)</td><td align="left">224.52</td><td align="left">564.15 (349.53, 826.08)</td><td align="left">602.90 (369.31, 893.14)</td><td align="left">6.87</td><td align="left">0.22 (0.20, 0.23)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;North Africa and Middle East</td><td align="left">53938.36 (33015.68, 81595.75)</td><td align="left">183998.40 (112447.97, 265772.20)</td><td align="left">241.13</td><td align="left">295.11 (180.20, 442.59)</td><td align="left">372.57 (227.14, 537.23)</td><td align="left">26.25</td><td align="left">0.75 (0.71, 0.78)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;South Asia</td><td align="left">208402.15 (123357.58, 323883.42)</td><td align="left">645535.63 (441050.54, 923835.43)</td><td align="left">209.75</td><td align="left">347.96 (205.56, 540.24)</td><td align="left">384.24 (262.58, 548.09)</td><td align="left">10.43</td><td align="left">0.29 (0.24, 0.33)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;East Asia</td><td align="left">247287.86 (161786.81, 364496.99)</td><td align="left">833451.31 (549170.97, 1192113.23)</td><td align="left">237.04</td><td align="left">254.28 (166.09, 374.05)</td><td align="left">305.92 (201.23, 437.11)</td><td align="left">20.31</td><td align="left">0.65 (0.50, 0.83)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Oceania</td><td align="left">944.04 (444.68, 1585.82)</td><td align="left">2327.52 (1130.05, 3776.64)</td><td align="left">146.55</td><td align="left">314.73 (150.59, 523.66)</td><td align="left">310.80 (153.56, 499.72)</td><td align="left">&#x02212;1.25</td><td align="left">&#x02212;0.05 (&#x02212;0.06, &#x02212;0.04)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southeast Asia</td><td align="left">76276.87 (49699.82, 113748.19)</td><td align="left">293089.21 (180806.41, 426938.88)</td><td align="left">284.24</td><td align="left">278.40 (181.48, 414.19)</td><td align="left">392.85 (241.91, 570.95)</td><td align="left">41.11</td><td align="left">1.11 (1.09, 1.12)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Sub-Saharan Africa</td><td align="left">13968.64 (5054.43, 24860.73)</td><td align="left">31953.73 (14271.17, 52631.46)</td><td align="left">128.75</td><td align="left">606.95 (219.22, 1078.47)</td><td align="left">589.65 (260.77, 970.78)</td><td align="left">&#x02212;2.85</td><td align="left">&#x02212;0.12 (&#x02212;0.15, &#x02212;0.09)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Eastern Sub-Saharan Africa</td><td align="left">34663.86 (19448.65, 55113.12)</td><td align="left">84190.88 (54085.13, 122506.46)</td><td align="left">142.88</td><td align="left">448.70 (251.73, 712.11)</td><td align="left">492.85 (314.65, 714.43)</td><td align="left">9.84</td><td align="left">0.31 (0.29, 0.34)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Sub-Saharan Africa</td><td align="left">16880.26 (10,420.35, 24912.61)</td><td align="left">39533.56 (25276.10, 58389.82)</td><td align="left">134.20</td><td align="left">553.68 (340.26, 813.86)</td><td align="left">612.55 (390.58, 903.20)</td><td align="left">10.63</td><td align="left">0.33 (0.30, 0.35)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Sub-Saharan Africa</td><td align="left">46474.95 (27722.60, 72102.02)</td><td align="left">116239.72 (78462.83, 166115.59)</td><td align="left">150.11</td><td align="left">488.05 (289.77, 756.62)</td><td align="left">579.13 (390.42, 825.89)</td><td align="left">18.66</td><td align="left">0.56 (0.55, 0.58)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Numbers and ASRs per 100,000 cases of mortality of elderly epilepsy in 1990 and 2021, along with the relative changes and AAPC in ASRs per 100,000 cases from 1990 to 2021, categorized by global, SDI, and GBD regions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Number (95%UI) In 1990</th><th align="left">Number (95%UI) In 2021</th><th align="left">Relative change of numbers from 1990 to 2021 (%)</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 1990</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 2021</th><th align="left">Relative change of age-standardized rate from 1990 to 2021 (%)</th><th align="left">AAPC, 95%CI (%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Global</td><td align="left">17356.79 (14130.44, 19473.12)</td><td align="left">41943.04 (33516.22, 46206.15)</td><td align="left">141.65</td><td align="left">3.82 (3.11, 4.29)</td><td align="left">3.99 (3.18, 4.39)</td><td align="left">4.45</td><td align="left">0.16 (0.11, 0.22)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="9">SDI Regions</td></tr><tr><td align="left">&#x02003;High SDI</td><td align="left">2910.01 (2703.39, 3050.13)</td><td align="left">10205.56 (8651.23, 11234.60)</td><td align="left">250.71</td><td align="left">2.03 (1.88, 2.14)</td><td align="left">3.38 (2.90, 3.70)</td><td align="left">66.50</td><td align="left">1.64 (1.57, 1.71)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-middle SDI</td><td align="left">2206.59 (1984.84, 2542.05)</td><td align="left">5679.04 (4718.31, 6284.60)</td><td align="left">157.37</td><td align="left">1.90 (1.70, 2.20)</td><td align="left">2.31 (1.92, 2.56)</td><td align="left">21.58</td><td align="left">0.67 (0.62, 0.72)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Middle SDI</td><td align="left">3323.86 (2811.65, 3978.04)</td><td align="left">7683.83 (6308.99, 8747.35)</td><td align="left">131.17</td><td align="left">3.19 (2.68, 3.81)</td><td align="left">2.52 (2.06, 2.87)</td><td align="left">&#x02212;21.00</td><td align="left">&#x02212;0.74 (&#x02212;0.80, &#x02212;0.68)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low-middle SDI</td><td align="left">4803.41 (3170.26, 5839.70)</td><td align="left">11047.03 (7561.62, 12877.46)</td><td align="left">129.98</td><td align="left">7.82 (5.18, 9.58)</td><td align="left">7.21 (4.91, 8.46)</td><td align="left">&#x02212;7.80</td><td align="left">&#x02212;0.24 (&#x02212;0.32, &#x02212;0.17)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low SDI</td><td align="left">4096.06 (3169.74, 5051.89)</td><td align="left">7287.23 (5654.84, 8667.00)</td><td align="left">77.91</td><td align="left">18.70 (14.30, 23.22)</td><td align="left">14.94 (11.42, 17.83)</td><td align="left">&#x02212;20.11</td><td align="left">&#x02212;0.71 (&#x02212;0.75, &#x02212;0.68)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Asia</td><td align="left">103.68 (94.33, 118.04)</td><td align="left">248.59 (213.87, 280.38)</td><td align="left">139.77</td><td align="left">1.85 (1.68, 2.12)</td><td align="left">2.58 (2.21, 2.91)</td><td align="left">39.46</td><td align="left">0.94 (0.74, 1.14)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Europe</td><td align="left">416.76 (385.69, 456.97)</td><td align="left">1219.61 (1004.69, 1373.60)</td><td align="left">192.64</td><td align="left">2.22 (2.05, 2.45)</td><td align="left">4.07 (3.34, 4.59)</td><td align="left">83.33</td><td align="left">2.08 (1.94, 2.21)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Eastern Europe</td><td align="left">364.54 (349.13, 377.72)</td><td align="left">565.54 (481.86, 635.72)</td><td align="left">55.14</td><td align="left">1.07 (1.01, 1.11)</td><td align="left">1.24 (1.06, 1.39)</td><td align="left">15.89</td><td align="left">0.66 (0.47, 0.84)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Australasia</td><td align="left">69.64 (61.55, 77.66)</td><td align="left">152.14 (127.84, 173.99)</td><td align="left">118.47</td><td align="left">2.31 (2.04, 2.59)</td><td align="left">2.04 (1.72, 2.32)</td><td align="left">&#x02212;11.69</td><td align="left">&#x02212;0.36 (&#x02212;0.61, &#x02212;0.12)</td><td align="left">0.025</td></tr><tr><td align="left">&#x02003;High-income Asia Pacific</td><td align="left">175.60 (149.18, 229.26)</td><td align="left">1571.43 (1241.88, 1812.09)</td><td align="left">794.89</td><td align="left">0.74 (0.62, 0.96)</td><td align="left">2.06 (1.67, 2.35)</td><td align="left">178.38</td><td align="left">3.33 (3.14, 3.54)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-income North America</td><td align="left">680.08 (623.77, 717.24)</td><td align="left">1952.24 (1726.75, 2104.56)</td><td align="left">187.06</td><td align="left">1.45 (1.33, 1.53)</td><td align="left">2.17 (1.93, 2.34)</td><td align="left">49.66</td><td align="left">1.32 (1.19, 1.46)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Latin America</td><td align="left">109.58 (98.17, 121.79)</td><td align="left">277.99 (241.94, 312.88)</td><td align="left">153.69</td><td align="left">1.94 (1.73, 2.16)</td><td align="left">2.43 (2.12, 2.74)</td><td align="left">25.26</td><td align="left">0.72 (0.60, 0.83)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Europe</td><td align="left">2032.00 (1880.26, 2144.96)</td><td align="left">7675.49 (6372.83, 8584.61)</td><td align="left">277.73</td><td align="left">2.65 (2.45, 2.80)</td><td align="left">5.43 (4.57, 6.04)</td><td align="left">104.91</td><td align="left">2.31 (2.21, 2.40)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Andean Latin America</td><td align="left">94.42 (76.15, 113.22)</td><td align="left">187.87 (145.97, 235.02)</td><td align="left">98.97</td><td align="left">4.11 (3.31, 4.93)</td><td align="left">2.64 (2.05, 3.30)</td><td align="left">&#x02212;35.77</td><td align="left">&#x02212;1.45 (&#x02212;1.61, &#x02212;1.32)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Caribbean</td><td align="left">149.12 (130.52, 172.84)</td><td align="left">245.32 (204.05, 293.72)</td><td align="left">64.51</td><td align="left">4.84 (4.23, 5.60)</td><td align="left">3.63 (3.02, 4.35)</td><td align="left">&#x02212;25.00</td><td align="left">&#x02212;0.79 (&#x02212;0.95, &#x02212;0.61)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Latin America</td><td align="left">403.51 (380.43, 424.10)</td><td align="left">1157.89 (1021.68, 1294.74)</td><td align="left">186.95</td><td align="left">4.52 (4.24, 4.77)</td><td align="left">3.83 (3.38, 4.28)</td><td align="left">&#x02212;15.27</td><td align="left">&#x02212;0.52 (&#x02212;0.61, &#x02212;0.42)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Tropical Latin America</td><td align="left">195.14 (181.03, 207.21)</td><td align="left">1217.36 (1085.79, 1317.37)</td><td align="left">523.84</td><td align="left">1.98 (1.81, 2.12)</td><td align="left">3.88 (3.45, 4.20)</td><td align="left">95.96</td><td align="left">2.21 (2.11, 2.30)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;North Africa and Middle East</td><td align="left">729.88 (574.93, 1039.28)</td><td align="left">1463.72 (1152.91, 1864.71)</td><td align="left">100.54</td><td align="left">4.50 (3.48, 6.58)</td><td align="left">3.28 (2.57, 4.26)</td><td align="left">&#x02212;27.11</td><td align="left">&#x02212;1.00 (&#x02212;1.03, &#x02212;0.96)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;South Asia</td><td align="left">5351.27 (3183.17, 6642.74)</td><td align="left">12744.16 (8305.09, 15031.78)</td><td align="left">138.15</td><td align="left">9.64 (5.69, 12.13)</td><td align="left">8.22 (5.29, 9.77)</td><td align="left">&#x02212;14.73</td><td align="left">&#x02212;0.46 (&#x02212;0.54, &#x02212;0.36)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;East Asia</td><td align="left">1978.90 (1642.52, 2682.34)</td><td align="left">3035.94 (2394.55, 3900.41)</td><td align="left">53.42</td><td align="left">2.13 (1.76, 2.90)</td><td align="left">1.16 (0.91, 1.49)</td><td align="left">&#x02212;45.54</td><td align="left">&#x02212;1.92 (&#x02212;1.95, &#x02212;1.88)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Oceania</td><td align="left">4.85 (2.87, 8.17)</td><td align="left">12.43 (7.81, 19.77)</td><td align="left">156.29</td><td align="left">1.81 (1.07, 3.07)</td><td align="left">1.77 (1.10, 2.83)</td><td align="left">&#x02212;2.21</td><td align="left">&#x02212;0.06 (&#x02212;0.08, &#x02212;0.04)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southeast Asia</td><td align="left">551.98 (414.56, 693.44)</td><td align="left">1207.42 (893.61, 1535.64)</td><td align="left">118.74</td><td align="left">2.19 (1.65, 2.78)</td><td align="left">1.80 (1.34, 2.30)</td><td align="left">&#x02212;17.81</td><td align="left">&#x02212;0.63 (&#x02212;0.66, &#x02212;0.60)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Sub-Saharan Africa</td><td align="left">197.95 (135.10, 284.41)</td><td align="left">383.16 (251.91, 569.07)</td><td align="left">93.56</td><td align="left">9.33 (6.32, 13.53)</td><td align="left">7.33 (4.78, 10.93)</td><td align="left">&#x02212;21.44</td><td align="left">&#x02212;0.76 (&#x02212;0.78, &#x02212;0.75)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Eastern Sub-Saharan Africa</td><td align="left">2684.59 (2097.25, 3305.03)</td><td align="left">4437.19 (3597.83, 5506.09)</td><td align="left">65.28</td><td align="left">38.23 (29.60, 47.52)</td><td align="left">28.25 (22.73, 35.11)</td><td align="left">&#x02212;26.11</td><td align="left">&#x02212;0.96 (&#x02212;0.98, &#x02212;0.95)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Sub-Saharan Africa</td><td align="left">148.42 (110.39, 194.54)</td><td align="left">275.37 (206.16, 332.63)</td><td align="left">85.53</td><td align="left">5.01 (3.71, 6.65)</td><td align="left">4.32 (3.19, 5.23)</td><td align="left">&#x02212;13.77</td><td align="left">&#x02212;0.47 (&#x02212;0.50, &#x02212;0.44)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Sub-Saharan Africa</td><td align="left">914.89 (662.33, 1304.98)</td><td align="left">1912.21 (1238.41, 2370.24)</td><td align="left">109.01</td><td align="left">9.45 (6.73, 13.57)</td><td align="left">9.52 (6.18, 11.79)</td><td align="left">0.74</td><td align="left">0.05 (0.03, 0.07)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr></tbody></table></table-wrap><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Numbers and ASRs per 100,000 cases of DALYs of elderly epilepsy in 1990 and 2021, along with the relative changes and AAPC in ASRs per 100,000 cases from 1990 to 2021, categorized by global, SDI, and GBD regions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Number (95%UI) In 1990</th><th align="left">Number (95%UI) In 2021</th><th align="left">Relative change of numbers from 1990 to 2021 (%)</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 1990</th><th align="left">Age-standardized rate (95%UI) (/100, 000) In 2021</th><th align="left">Relative change of age-standardized rate from 1990 to 2021 (%)</th><th align="left">AAPC, 95%CI (%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Global</td><td align="left">839396.84 (627388.56, 1115077.55)</td><td align="left">1899781.45 (1387299.39, 2619442.51)</td><td align="left">126.33</td><td align="left">175.45 (130.74, 233.25)</td><td align="left">176.01 (128.42, 242.74)</td><td align="left">0.32</td><td align="left">0.02 (0.01, 0.04)</td><td align="left">0.002</td></tr><tr><td align="left" colspan="9">SDI Regions</td></tr><tr><td align="left">&#x02003;High SDI</td><td align="left">187179.75 (124944.46, 283431.46)</td><td align="left">464782.37 (303999.81, 714674.91)</td><td align="left">148.31</td><td align="left">130.10 (86.85, 197.01)</td><td align="left">164.91 (107.80, 253.90)</td><td align="left">26.76</td><td align="left">0.77 (0.74, 0.79)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-middle SDI</td><td align="left">153409.03 (107336.31, 218965.79)</td><td align="left">305739.73 (204827.45, 457917.19)</td><td align="left">99.30</td><td align="left">123.33 (86.10, 175.71)</td><td align="left">120.35 (80.71, 179.95)</td><td align="left">&#x02212;2.42</td><td align="left">&#x02212;0.06 (&#x02212;0.09, &#x02212;0.01)</td><td align="left">0.021</td></tr><tr><td align="left">&#x02003;Middle SDI</td><td align="left">194966.74 (139480.64, 267647.21)</td><td align="left">495800.22 (344068.67, 714010.41)</td><td align="left">154.30</td><td align="left">169.14 (120.55, 232.01)</td><td align="left">153.14 (106.17, 220.44)</td><td align="left">&#x02212;9.46</td><td align="left">&#x02212;0.30 (&#x02212;0.33, &#x02212;0.28)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low-middle SDI</td><td align="left">182949.65 (130819.32, 244966.39)</td><td align="left">413813.72 (308723.34, 531848.04)</td><td align="left">126.19</td><td align="left">271.12 (193.27, 363.90)</td><td align="left">249.58 (185.81, 321.14)</td><td align="left">&#x02212;7.94</td><td align="left">&#x02212;0.26 (&#x02212;0.29, &#x02212;0.22)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low SDI</td><td align="left">119914.60 (91583.13, 153956.40)</td><td align="left">217796.86 (170365.31, 271870.40)</td><td align="left">81.63</td><td align="left">490.10 (372.06, 630.11)</td><td align="left">403.26 (314.50, 503.50)</td><td align="left">&#x02212;17.72</td><td align="left">&#x02212;0.62 (&#x02212;0.63, &#x02212;0.61)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Asia</td><td align="left">9601.89 (5908.45, 14770.67)</td><td align="left">20129.06 (12876.41, 30227.63)</td><td align="left">109.64</td><td align="left">167.01 (101.98, 257.47)</td><td align="left">199.51 (127.06, 299.38)</td><td align="left">19.46</td><td align="left">0.55 (0.50, 0.61)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Europe</td><td align="left">30430.69 (20682.43, 44295.92)</td><td align="left">55478.88 (39658.49, 78727.78)</td><td align="left">82.31</td><td align="left">153.63 (104.51, 222.89)</td><td align="left">187.04 (133.76, 265.14)</td><td align="left">21.75</td><td align="left">0.67 (0.63, 0.71)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Eastern Europe</td><td align="left">36279.34 (24040.69, 56120.65)</td><td align="left">43043.44 (26791.37, 67067.88)</td><td align="left">18.64</td><td align="left">98.30 (64.97, 152.06)</td><td align="left">89.97 (56.22, 139.78)</td><td align="left">&#x02212;8.47</td><td align="left">&#x02212;0.29 (&#x02212;0.33, &#x02212;0.25)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Australasia</td><td align="left">3967.00 (2049.04, 7402.05)</td><td align="left">8218.63 (3946.72, 16061.24)</td><td align="left">107.17</td><td align="left">129.02 (66.60, 240.58)</td><td align="left">115.42 (55.45, 225.73)</td><td align="left">&#x02212;10.54</td><td align="left">&#x02212;0.31 (&#x02212;0.38, &#x02212;0.25)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-income Asia Pacific</td><td align="left">22255.60 (12654.03, 36845.55)</td><td align="left">73686.67 (44458.71, 120144.94)</td><td align="left">231.09</td><td align="left">89.39 (50.88, 147.91)</td><td align="left">115.48 (68.63, 190.37)</td><td align="left">29.19</td><td align="left">0.82 (0.77, 0.85)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;High-income North America</td><td align="left">44712.35 (28725.12, 68627.65)</td><td align="left">122667.74 (75846.01, 193426.23)</td><td align="left">174.35</td><td align="left">96.45 (61.99, 148.09)</td><td align="left">138.03 (85.48, 217.69)</td><td align="left">43.11</td><td align="left">1.20 (1.13, 1.28)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Latin America</td><td align="left">7503.41 (4228.63, 12147.03)</td><td align="left">15710.30 (9087.29, 25205.23)</td><td align="left">109.38</td><td align="left">128.22 (72.10, 207.30)</td><td align="left">139.31 (80.58, 223.58)</td><td align="left">8.65</td><td align="left">0.28 (0.24, 0.32)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Europe</td><td align="left">116108.60 (77662.70, 177238.81)</td><td align="left">265661.70 (181145.63, 405782.49)</td><td align="left">128.80</td><td align="left">151.95 (101.73, 231.80)</td><td align="left">210.14 (142.78, 322.33)</td><td align="left">38.30</td><td align="left">1.04 (1.00, 1.08)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Andean Latin America</td><td align="left">7478.42 (4116.70, 11979.11)</td><td align="left">17713.25 (9927.16, 29523.81)</td><td align="left">136.86</td><td align="left">316.51 (173.43, 507.66)</td><td align="left">246.57 (138.06, 411.00)</td><td align="left">&#x02212;22.10</td><td align="left">&#x02212;0.80 (&#x02212;0.84, &#x02212;0.76)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Caribbean</td><td align="left">7244.31 (5147.08, 10182.50)</td><td align="left">12871.53 (8777.38, 18328.89)</td><td align="left">77.68</td><td align="left">228.09 (161.73, 320.68)</td><td align="left">191.35 (130.62, 272.24)</td><td align="left">&#x02212;16.11</td><td align="left">&#x02212;0.51 (&#x02212;0.56, &#x02212;0.45)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Latin America</td><td align="left">28632.97 (19804.36, 40411.62)</td><td align="left">80400.10 (55192.85, 117490.74)</td><td align="left">180.80</td><td align="left">302.26 (208.99, 427.12)</td><td align="left">261.17 (179.20, 381.43)</td><td align="left">&#x02212;13.59</td><td align="left">&#x02212;0.46 (&#x02212;0.49, &#x02212;0.43)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Tropical Latin America</td><td align="left">22944.65 (14417.07, 36018.74)</td><td align="left">74370.54 (49626.38, 111140.46)</td><td align="left">224.13</td><td align="left">216.14 (135.89, 338.76)</td><td align="left">232.00 (154.64, 346.62)</td><td align="left">7.34</td><td align="left">0.23 (0.21, 0.25)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;North Africa and Middle East</td><td align="left">32283.57 (22761.90, 45654.04)</td><td align="left">74592.61 (50708.52, 109499.24)</td><td align="left">131.05</td><td align="left">175.33 (123.40, 247.70)</td><td align="left">150.39 (102.40, 219.97)</td><td align="left">&#x02212;14.22</td><td align="left">&#x02212;0.50 (&#x02212;0.53, &#x02212;0.48)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;South Asia</td><td align="left">186363.41 (125928.82, 251136.14)</td><td align="left">433717.86 (316634.96, 552403.93)</td><td align="left">132.73</td><td align="left">300.73 (202.24, 406.47)</td><td align="left">254.68 (184.94, 324.78)</td><td align="left">&#x02212;15.31</td><td align="left">&#x02212;0.51 (&#x02212;0.56, &#x02212;0.46)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;East Asia</td><td align="left">124288.15 (85111.08, 179399.21)</td><td align="left">260419.50 (161645.25, 408599.25)</td><td align="left">109.53</td><td align="left">123.63 (84.10, 178.60)</td><td align="left">95.02 (58.93, 148.84)</td><td align="left">&#x02212;23.14</td><td align="left">&#x02212;0.81 (&#x02212;0.91, &#x02212;0.70)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Oceania</td><td align="left">441.36 (226.32, 755.35)</td><td align="left">1045.05 (557.16, 1726.28)</td><td align="left">136.78</td><td align="left">143.34 (74.46, 242.59)</td><td align="left">135.69 (72.34, 223.78)</td><td align="left">&#x02212;5.34</td><td align="left">&#x02212;0.18 (&#x02212;0.19, &#x02212;0.17)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southeast Asia</td><td align="left">37419.15 (25137.38, 54909.36)</td><td align="left">108840.43 (67650.60, 166263.22)</td><td align="left">190.87</td><td align="left">134.40 (90.00, 196.79)</td><td align="left">144.31 (89.62, 220.24)</td><td align="left">7.37</td><td align="left">0.22 (0.19, 0.23)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Central Sub-Saharan Africa</td><td align="left">9827.98 (5762.30, 15209.33)</td><td align="left">19599.76 (12082.65, 30176.11)</td><td align="left">99.43</td><td align="left">407.70 (234.92, 636.90)</td><td align="left">344.54 (208.26, 531.32)</td><td align="left">&#x02212;15.49</td><td align="left">&#x02212;0.55 (&#x02212;0.57, &#x02212;0.53)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Eastern Sub-Saharan Africa</td><td align="left">65953.16 (51677.23, 82024.80)</td><td align="left">114317.26 (91707.98, 141697.63)</td><td align="left">73.33</td><td align="left">839.39 (654.83, 1045.98)</td><td align="left">663.25 (531.25, 820.87)</td><td align="left">&#x02212;20.98</td><td align="left">&#x02212;0.75 (&#x02212;0.76, &#x02212;0.74)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Southern Sub-Saharan Africa</td><td align="left">8642.86 (5854.88, 12384.94)</td><td align="left">17632.97 (12041.87, 25219.13)</td><td align="left">104.02</td><td align="left">278.03 (187.33, 398.41)</td><td align="left">265.01 (179.30, 380.47)</td><td align="left">&#x02212;4.68</td><td align="left">&#x02212;0.15 (&#x02212;0.17, &#x02212;0.14)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Western Sub-Saharan Africa</td><td align="left">37017.98 (25975.00, 52473.03)</td><td align="left">79664.16 (57154.41, 104790.43)</td><td align="left">115.20</td><td align="left">367.20 (254.69, 522.96)</td><td align="left">378.11 (269.94, 500.01)</td><td align="left">2.97</td><td align="left">0.10 (0.08, 0.11)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr></tbody></table></table-wrap></p><p id="Par29">An in-depth analysis using the AAPC revealed distinct temporal trends. The incidence rates demonstrated an AAPC of 0.78 (1990&#x02013;2021), decreasing to 0.53 (2012&#x02013;2021). Similarly, the prevalence rates declined from 0.60 to 0.28. Mortality rates exhibited a modest AAPC of 0.16 (1990&#x02013;2021), decreasing to 0.09 (2012&#x02013;2021). DALY rates shifted from minimal change (AAPC: 0.02) to a negative trend (AAPC: &#x02212;0.10) in 2012&#x02013;2021 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Forest plot of AAPC in ASIR, ASMR, ASPR and ASDR of elderly epilepsy for 21 GBD regions from 1990 to 2021 and 2012 to 2021. ASIR (A), ASMR (B), ASPR (C), ASDR (D). AAPC&#x02009;=&#x02009;average annual percentage change. ASIR&#x02009;=&#x02009;age-standardized incidence rate. ASMR&#x02009;=&#x02009;age-standardized mortality rate. ASPR&#x02009;=&#x02009;age-standardized prevalence rate. ASDR&#x02009;=&#x02009;age-standardized DALYs rate. DALYs&#x02009;=&#x02009;disability adjusted life years</p></caption><graphic xlink:href="12916_2025_4268_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec10"><title>Regional trends</title><p id="Par30">Across 21 GBD regions, Western Europe had the highest 2021 ASIR of 50.85 (95% UI: 27.19&#x02013;77.66) per 100,000, while Eastern Europe recorded the lowest at 17.02 (95% UI: 9.06&#x02013;27.70) per 100,000. High-income North America displayed a substantial ASIR increase of 64.47% with an AAPC of 1.63% (95% CI: 1.52&#x02013;1.75%), while Oceania showed the lowest increase of 1.03% in ASIR with an AAPC of 0.03% (95% CI: 0.02&#x02013;0.04%). For prevalence, Andean Latin America reported the highest ASPR at 726.39 (95% UI: 376.62&#x02013;1138.73) per 100,000, with Eastern Europe having the lowest at 296.32 (95% UI: 192.32&#x02013;429.44) per 100,000. Central Sub-Saharan Africa and Oceania experienced slight ASPR declines (Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>).
</p><p id="Par31">High-income Asia Pacific experienced a significant increase in the absolute number of deaths, rising by 794.89% with a relative change in ASMR of 178.38% and an AAPC of 3.33% (95% CI: 3.14&#x02013;3.54%) from 1990 to 2021,&#x000a0;while East Asia's ASMR declined 45.54% despite a 53.42% increase in absolute deaths. High-income Asia Pacific demonstrated the most pronounced relative change in DALYs (231.09%) with a 29.19% increase in ASDR and an AAPC of 0.82% (95% CI: 0.77&#x02013;0.85%), while East Asia and Andean Latin America showed declining trends despite absolute increases (Tables <xref rid="Tab3" ref-type="table">3</xref> and <xref rid="Tab4" ref-type="table">4</xref>).
</p></sec><sec id="Sec11"><title>National trends</title><p id="Par32">Among 204 countries and territories, Qatar showed the most notable increases of 916.74% for incidence and 777.24% for prevalence. In contrast, only Nauru, Georgia, and Afghanistan reported declines in both incidence and prevalence. Mortality rates were diverse, with Japan recording the highest increase at 1191.90%, while Ukraine showed the most significant decrease of 28.05%.&#x000a0;For DALYs, Qatar reported the steepest rise of 485.13%, whereas Tokelau had the highest drop of 13.79% (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S1-S4).</p><p id="Par33">When considering ASRs, Germany exhibited an increase of 116.29% in incidence, with an AAPC of 2.51% (95% CI: 2.47&#x02013;2.55%), and a 91.14% increase in DALYs, accompanied by an AAPC of 2.13% (95% CI: 2.05&#x02013;2.20%), leading the upward trends. In contrast, countries like Nauru experienced a decrease of 27.75% in incidence, with an AAPC of &#x02212;1.07% (95% CI: &#x02212;1.24 to &#x02212;0.93%), and Bermuda reported a decrease of 41.75% in DALYs, with an AAPC of &#x02212;1.72% (95% CI: &#x02212;1.78 to &#x02212;1.67%), marking a decline in their respective trends (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S1&#x02013;S4, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Distribution of ASIR, ASMR, ASPR and ASDR attributable to elderly epilepsy in 204 countries in 2021. ASIR in 2021 (<bold>A</bold>), ASMR (<bold>B</bold>), ASPR (<bold>C</bold>), ASDR (<bold>D</bold>). ASIR&#x02009;=&#x02009;age-standardized incidence rate. ASMR&#x02009;=&#x02009;age-standardized mortality rate. ASPR&#x02009;=&#x02009;age-standardized prevalence rate. ASDR&#x02009;=&#x02009;age-standardized DALYs rate. DALYs&#x02009;=&#x02009;disability adjusted life years</p></caption><graphic xlink:href="12916_2025_4268_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Burden of epilepsy by sex and age in 2021</title><p id="Par34">Sex-specific analysis revealed distinct patterns across global, regional and national levels in 2021 (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S5). Males generally had higher ASIR, ASMR, ASPR, and ASDR than females, with exceptions in specific regions. In Andean Latin America, Southeast Asia, South Asia, and Oceania, females had higher ASIR (highest in Malaysia: 44.72 vs. 34.03 per 100,000). South Asia reported higher ASMR for females (highest in Pakistan: 22.31 vs. 8.56 per 100,000), while Andean Latin America, Southeast Asia, Central Latin America, and South Asia showed higher ASPR for females (highest in Afghanistan: 342.30 vs. 185.71 per 100,000). For ASDR, South Asia had higher rates for females (highest in Pakistan: 524.99 vs. 241.89 per 100,000).</p><p id="Par35">Age-related patterns revealed declining absolute numbers with increasing age, except for peaks at 65&#x02013;69 (prevalence) and 70&#x02013;74 (mortality) years. However, age-specific rates increased steadily with age, peaking in the 95&#x02009;+&#x02009;population, with males consistently showing higher rates across all age groups (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S6, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Distribution of incidence, mortality, prevalence and DALYs rate of elderly epilepsy by age and sex in global in 2021. Incidence in 2021 (<bold>A</bold>), mortality (<bold>B</bold>), prevalence (<bold>C</bold>), DALYs rate (<bold>D</bold>). DALYs&#x02009;=&#x02009;disability adjusted life years</p></caption><graphic xlink:href="12916_2025_4268_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>Socioeconomic disparity of epilepsy burden</title><p id="Par36">Analysis of epilepsy burden across the 21 GBD regions revealed complex associations with socio-demographic development. The ASIR showed a weak negative correlation with the SDI (&#x003c1;&#x02009;=&#x02009;&#x02212;0.21, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), while the ASPR demonstrated a slight positive correlation (&#x003c1;&#x02009;=&#x02009;0.08, <italic>P</italic>&#x02009;=&#x02009;0.025). Both exhibited non-linear patterns, with initial decline followed by uptick in higher SDI regions, particularly in Western Europe and High-income North America. Stronger negative correlations emerged for mortality (&#x003c1;&#x02009;=&#x02009;&#x02212;0.58, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and DALYs (&#x003c1;&#x02009;=&#x02009;&#x02212;0.69, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) rates with SDI. These findings suggest that while epilepsy occurrence patterns show minimal relationship with socio-demographic development, outcomes significantly improve in higher-SDI regions (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>ASIR, ASMR, ASPR and ASDR due to elderly epilepsy for 21 GBD regions by SDI, 1990&#x02013;2021. ASIR (<bold>A</bold>), ASMR (<bold>B</bold>), ASPR (<bold>C</bold>), ASDR (<bold>D</bold>).ASIR&#x02009;=&#x02009;age-standardized incidence rate. ASMR&#x02009;=&#x02009;age-standardized mortality rate. ASPR&#x02009;=&#x02009;age-standardized prevalence rate. ASDR&#x02009;=&#x02009;age-standardized DALYs rate. DALYs&#x02009;=&#x02009;disability adjusted life years. SDI&#x02009;=&#x02009;socio-demographic Index</p></caption><graphic xlink:href="12916_2025_4268_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title>Decomposition of driving factors for the burden of epilepsy</title><p id="Par37">From 1990 to 2021, driving factors behind epilepsy burden changes demonstrated substantial regional heterogeneity (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S7).&#x000a0;Population growth emerged as the predominant contributor to increases across all metrics.&#x000a0;Only high-SDI regions exhibited increases in both deaths and DALYs attributable to epidemiological factors, particularly in Western Europe, High-income North America, and High-income Asia Pacific regions.&#x000a0;Conversely, South Asia, East Asia, and Eastern Sub-Saharan Africa showed substantial epidemiological improvements.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Decomposition of changes in the number of incidence, mortality, prevalence and DALYs of elderly epilepsy for 21 GBD regions from 1990 to 2021, based on population-level determinants of population aging, population growth, and epidemiological changes. Number of incidence (<bold>A</bold>), Number of mortality (<bold>B</bold>), Number of prevalence (<bold>C</bold>), Number of DALYs (<bold>D</bold>). DALYs&#x02009;=&#x02009;disability adjusted life years</p></caption><graphic xlink:href="12916_2025_4268_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec15"><title>Trend and prediction of epilepsy burden</title><p id="Par38">Projection data shows ASIR rose from approximately 25.06 per 100,000 in 1990 to 31.72 per 100,000 in 2021, with further increases projected (AAPC: 1.64%, 95% CI: 1.59&#x02013;1.69%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) from 2022 through 2035.&#x000a0;Similarly, ASPR increased from about 355.34 per 100,000 in 1990 to 426.46 per 100,000 in 2021, with continued growth expected (AAPC: 1.34%, 95% CI: 1.31&#x02013;1.38%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). In contrast, while ASMR remained relatively stable between 3.81 and 4.01 per 100,000 from 1990 to 2021, projections indicate significant decline (AAPC: &#x02212;1.29%, 95% CI: &#x02212;1.33 to &#x02212;1.26%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) through 2035. The ASDR, which fluctuated around 175.44 to 176.04 per 100,000 during the observed period, is projected to show a modest decline (AAPC: &#x02212;0.12%, 95% CI: &#x02212;0.15 to &#x02212;0.10%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) in the coming years (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S8).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Changing trend and prediction rate of ASIR, ASMR, ASPR and ASDR of elderly epilepsy in global from 1990 to 2035. ASIR (<bold>A</bold>), ASMR (<bold>B</bold>), ASPR (<bold>C</bold>), ASDR (<bold>D</bold>). ASIR&#x02009;=&#x02009;age-standardized incidence rate. ASMR&#x02009;=&#x02009;age-standardized mortality rate. ASPR&#x02009;=&#x02009;age- standardized prevalence rate. ASDR&#x02009;=&#x02009;age-standardized DALYs rate. DALYs&#x02009;=&#x02009;disability adjusted life years. SDI&#x02009;=&#x02009;socio-demographic Index</p></caption><graphic xlink:href="12916_2025_4268_Fig6_HTML" id="MO6"/></fig></p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par39">From 1990 to 2021, epilepsy showed significant increases in both absolute and age-standardized metrics globally, particularly among those aged 60&#x000a0;years and above. The substantial rise in absolute numbers can be largely attributed to population growth and aging [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], especially in populous nations like India and China.&#x000a0;While previous studies reported declining overall ASMR (&#x02212;24.5%) and ASDR (&#x02212;19.4%) from 1990 to 2016 across all age groups [<xref ref-type="bibr" rid="CR7">7</xref>], our analysis reveals a different trajectory for the elderly, with slightly increasing ASMR and ASDR. These findings suggest that despite significant advances in medical care and improved public awareness of epilepsy [<xref ref-type="bibr" rid="CR29">29</xref>], the persistently elevated mortality in the older population may reflect several unresolved management barriers, including: (1) diagnostic delays due to atypical presentations [<xref ref-type="bibr" rid="CR10">10</xref>] and witness scarcity [<xref ref-type="bibr" rid="CR30">30</xref>]; (2) treatment optimization challenges from polypharmacy interactions and increased neurotoxicity risks [<xref ref-type="bibr" rid="CR31">31</xref>]; and (3) social isolation contributing to increased risk of unwitnessed sudden unexpected death in epilepsy (SUDEP) [<xref ref-type="bibr" rid="CR12">12</xref>].&#x000a0;This persistent burden may be attributed to the complex interplay of multiple comorbidities and age-related health conditions among older adults, which often presents unique challenges that exceed the current capabilities of many global healthcare systems [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par40">Elderly epilepsy burden increased across all 21 GBD regions, primarily due to population growth and demographic aging. The geographical distribution of disease burden showed significant regional disparities, with distinct patterns emerging based on SDI. High SDI regions uniquely experienced simultaneous increases in both ASMR and ASDR, particularly in High-income Asia Pacific, Western Europe, and High-income North America. Conversely, East Asia and Andean Latin America showed declining trends in ASRs despite increases in absolute numbers. These divergent patterns highlight the necessity for regionally-tailored approaches to epilepsy management, with particular focus on areas experiencing rapid population aging and escalating disease burden.</p><p id="Par41">At the national level, rapidly developing nations like Qatar showed marked increases in elderly epilepsy incidence and prevalence, likely reflecting demographic shifts and improved diagnostics. Among developed nations, Japan's rising mortality aligns with its aging population and evolving neurological care practices, while Germany's consistent increases across all age-standardized metrics warrant careful examination of both epidemiological factors and potential systematic changes in clinical practice guidelines within its well-developed healthcare system. While some smaller nations showed declining trends, these patterns should be interpreted cautiously given their limited population base. These variations underscore the need for tailored epilepsy management strategies and standardized diagnostic criteria for cross-national comparisons in aging populations.</p><p id="Par42">Our findings support previous global reports showing males bear a greater burden of epilepsy than females [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], even among older populations. This sex disparity likely stems from biological factors, including male susceptibility to neuronal hyperexcitability, possibly due to differences in steroid hormones [<xref ref-type="bibr" rid="CR35">35</xref>]. Additionally, some studies found a higher incidence of SUDEP in males [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. However, it's worth noting that the apparent sex difference may be partially amplified by underreporting, as females may be more likely to conceal their epilepsy diagnosis in societies where such diagnosis could affect marriageability or lead to social marginalization [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Age remains a crucial determinant of epilepsy burden as the burden continues to increase with age, reaching its peak in those aged 95 and above in our study. These age and sex patterns underscore the need for targeted prevention and treatment strategies, particularly focusing on male patients and the advanced-age population.</p><p id="Par43">The burden of epilepsy demonstrated significant regional and socioeconomic variations across the globe. Our analysis revealed that while the relationship between socio-demographic development and disease occurrence (incidence and prevalence) was relatively modest, mortality and overall disease burden showed strong inverse correlations with SDI. This pattern was particularly evident in low and low-middle SDI, emphasizing the bidirectional relationship between epilepsy and poverty [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Inadequate medical infrastructure and limited access to services hinder their ability to address the growing burden [<xref ref-type="bibr" rid="CR6">6</xref>]. For instance, in Asia, low-income countries have only 0.03 neurologists per 100,000 population, compared to 2.96 in high-income countries [<xref ref-type="bibr" rid="CR40">40</xref>]. Additionally, high-SDI regions have seen significant increases in ASMR and ASDR for idiopathic epilepsy from 1990 to 2021. This pattern contrasts with previous findings from all-age studies covering 1990&#x02013;2019 [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. The persistent upward trend indicates an evolving public health challenge that requires focused research attention and targeted interventions in high-income regions.</p><p id="Par44">During 1990&#x02013;2021, population growth was the primary driver of increased epilepsy burden across all regions, with distinct regional epidemiological changes.&#x000a0;Notably, high-SDI regions, particularly in Western Europe, High-income North America, and High-income Asia Pacific, experienced rising deaths and DALYs likely due to improved detection and aging populations. To address this, prevention strategies should target modifiable risk factors in older populations, enhance specialized geriatric epilepsy care services, and improve surveillance systems to monitor trends and evaluate the effectiveness of interventions.</p><p id="Par45">Our BAPC analysis and projections through 2035 show that while incidence and prevalence rates of epilepsy are expected to rise (AAPC: 1.64% and 1.34%), mortality and DALY rates are declining (AAPC: &#x02212;1.29% and &#x02212;0.12%).&#x000a0;This indicates both challenges and progress in epilepsy management. The decline in mortality and DALY rates can be attributed to several factors: enhanced treatment protocols, improved healthcare access, and strengthened preventive strategies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. However, the rising incidence and prevalence among older populations remains a concern. Given these trends, future interventions should focus on two parallel tracks: maintaining the momentum in reducing mortality and disability while developing strategies to address the growing number of cases.</p><p id="Par46">The present study also had limitations. First, our reliance on the 1985 ILAE definition of idiopathic epilepsy from the GBD 2021 dataset, despite the 2017 ILAE Classification [<xref ref-type="bibr" rid="CR43">43</xref>], may impact trend interpretation, especially for recent years when clinical practice has evolved. While recategorization to current standards would be ideal, it's not feasible with existing GBD data. Second, the quality and completeness of data varied substantially across regions, with notable differences in data collection standards and accuracy. In regions with limited diagnostic resources, there is a higher probability of classifying epilepsy as'idiopathic'simply because underlying structural, vascular, or other causes cannot be adequately investigated. Third, our analysis spanning from 1990 to the present is subject to evolving diagnostic criteria and technological advancements, while our temporal trend analysis and forecasting were constrained by the cross-sectional nature of the data. Despite using sophisticated statistical methods (AAPC and BAPC), inherent uncertainties remain in long-term predictions. Finally, misclassification bias may have influenced our sex-specific findings. Some cases labeled'idiopathic'could have unrecognized acquired causes, potentially inflating male predominance given men's higher exposure to environmental risk factors. This would likely result in overestimation of male prevalence in idiopathic epilepsy.</p></sec><sec id="Sec17"><title>Conclusions</title><p id="Par47">Our study demonstrates that the global burden of idiopathic epilepsy in adults aged 60 and above increased substantially from 1990 to 2021, primarily driven by population growth. Males and advanced age groups showed higher vulnerability. Higher SDI regions experienced better outcomes in mortality and DALYs, despite showing unique increases in ASRs. Our projections through 2035 indicate divergent trends: rising incidence and prevalence rates but declining mortality and DALY rates. These findings emphasize the need for targeted interventions, particularly strengthening healthcare systems in resource-limited settings, enhancing specialized geriatric epilepsy care, and developing age-specific prevention strategies.&#x000a0;Strategic resource allocation and global cooperation remain crucial for addressing this evolving public health challenge.</p></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4268_MOESM1_ESM.zip"><caption><p>Additional file 1: Table S1. Numbers and ASRs per100,000 cases of incidence of elderly epilepsy among older population in 1990 and 2021, along with the relative changes and AAPC in ASRs per100,000 cases from 1990 to 2021, categorized by 204 countries and territories. Table S2. Numbers and ASRs per100,000 cases of prevalence of elderly epilepsy in 1990 and 2021, along with the relative changes and AAPC in ASRs per100,000 cases from 1990 to 2021, categorized by 204 countries and territories. Table S3. Numbers and ASRs per100,000 cases of mortality of elderly epilepsy in 1990 and 2021, along with the relative changes and AAPC in ASRs per100,000 cases from 1990 to 2021, categorized by 204 countries and territories. Table S4. Numbers and ASRs per100,000 cases of DALYs of elderly epilepsy in 1990 and 2021, along with the relative changes and AAPC in ASRs per100,000 cases from 1990 to 2021, categorized by 204 countries and territories. Table S5. Age-standardized incidence rate of incidence, mortality, prevalence and DALYs attributable to elderly epilepsy globally, regionally and nationally for male and female in 2021. Table S6. Incidence, mortality, prevalence and DALYs rate attributable to elderly epilepsy globally by age and sex in 2021. Table S7. Changes in number of incidence, mortality, prevalence and DALYs of elderly epilepsy for 21 GBD regions from 1990 to 2021, based on population-level determinants of population aging, population growth, and epidemiological changes. Table S8. Predicted ASIR, ASMR, ASPR and ASDR attributable to elderly epilepsy globally from 1990 to 2035.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AAPC</term><def><p id="Par5">Average annual percentage change</p></def></def-item><def-item><term>ASRs</term><def><p id="Par6">Age-standardized rates</p></def></def-item><def-item><term>ASIR</term><def><p id="Par7">Age-standardized incidence rate</p></def></def-item><def-item><term>ASMR</term><def><p id="Par8">Age-standardized mortality rate</p></def></def-item><def-item><term>ASPR</term><def><p id="Par9">Age-standardized prevalence rate</p></def></def-item><def-item><term>ASDR</term><def><p id="Par10">Age-standardized DALYs rate</p></def></def-item><def-item><term>BAPC</term><def><p id="Par11">Bayesian age-period-cohort</p></def></def-item><def-item><term>CI</term><def><p id="Par12">Confidence interval</p></def></def-item><def-item><term>DALYs</term><def><p id="Par13">Disability-adjusted life years</p></def></def-item><def-item><term>GBD</term><def><p id="Par14">Global Burden of Disease</p></def></def-item><def-item><term>SDI</term><def><p id="Par15">Socio-demographic Index</p></def></def-item><def-item><term>UI</term><def><p id="Par16">Uncertainty interval</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Jie Xue, Xiaopan Li and Yajun Zhao contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors gratefully acknowledge the Institute for Health Metrics and Evaluation (University of Washington), GBD Collaborators, and their staff for data provision.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>DJ and SFJ contributed to the study design and conceptualization. YJZ and XLW were responsible for data collection. YJZ and WCJ analyzed the data and contributed to its interpretation. JX and XPL drafted the manuscript and verified the data. All co-authors contributed to the critical revision of the manuscript. DJ and SFJ had final responsibility for the decision to submit for publication. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the National Key R&#x00026;D Program of China (Code: 2022YFC2503802), the Shanghai Public Health System Construction Three-year Action Plan Key Discipline Construction Program (GWVI-11.1&#x02013;44; to author SJ) and the Shanghai Action Plan for Science, Technology and Innovation (23JS1401000).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data from this study can be accessed openly through the GBD 2021 online database (https://ghdx.healthdata.org/gbd-results-tool), accessed on 14 January 2025.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par48">For the GBD is publicly available and no identifiable information was included in the analyses, the Ethical approval and informed consent were not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par49">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par50">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RS</given-names></name><name><surname>Acevedo</surname><given-names>C</given-names></name><name><surname>Arzimanoglou</surname><given-names>A</given-names></name><name><surname>Bogacz</surname><given-names>A</given-names></name><name><surname>Cross</surname><given-names>JH</given-names></name><name><surname>Elger</surname><given-names>CE</given-names></name><etal/></person-group><article-title>ILAE official report: a practical clinical definition of epilepsy</article-title><source>Epilepsia</source><year>2014</year><volume>55</volume><issue>4</issue><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">24730690</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475&#x02013;82.<pub-id pub-id-type="pmid">24730690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Thijs</surname><given-names>RD</given-names></name><name><surname>Surges</surname><given-names>R</given-names></name><name><surname>O'Brien</surname><given-names>TJ</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name></person-group><article-title>Epilepsy in adults</article-title><source>Lancet</source><year>2019</year><volume>393</volume><issue>10172</issue><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">30686584</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Thijs RD, Surges R, O&#x02019;Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689&#x02013;701.<pub-id pub-id-type="pmid">30686584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>CR</given-names></name><name><surname>Garcia</surname><given-names>HH</given-names></name></person-group><article-title>Epilepsy in poor regions of the world</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9848</issue><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">23021288</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Newton CR, Garcia HH. Epilepsy in poor regions of the world. Lancet. 2012;380(9848):1193&#x02013;201.<pub-id pub-id-type="pmid">23021288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Megiddo</surname><given-names>I</given-names></name><name><surname>Colson</surname><given-names>A</given-names></name><name><surname>Chisholm</surname><given-names>D</given-names></name><name><surname>Dua</surname><given-names>T</given-names></name><name><surname>Nandi</surname><given-names>A</given-names></name><name><surname>Laxminarayan</surname><given-names>R</given-names></name></person-group><article-title>Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model</article-title><source>Epilepsia</source><year>2016</year><volume>57</volume><issue>3</issue><fpage>464</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">26765291</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Megiddo I, Colson A, Chisholm D, Dua T, Nandi A, Laxminarayan R. Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model. Epilepsia. 2016;57(3):464&#x02013;74.<pub-id pub-id-type="pmid">26765291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>GS</given-names></name><name><surname>Dai</surname><given-names>XY</given-names></name><name><surname>Wu</surname><given-names>JZ</given-names></name><name><surname>Wang</surname><given-names>WZ</given-names></name><etal/></person-group><article-title>Primary care treatment of epilepsy with phenobarbital in rural China: cost-outcome analysis from the WHO/ILAE/IBE global campaign against epilepsy demonstration project</article-title><source>Epilepsia</source><year>2008</year><volume>49</volume><issue>3</issue><fpage>535</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">18302628</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ding D, Hong Z, Chen GS, Dai XY, Wu JZ, Wang WZ, et al. Primary care treatment of epilepsy with phenobarbital in rural China: cost-outcome analysis from the WHO/ILAE/IBE global campaign against epilepsy demonstration project. Epilepsia. 2008;49(3):535&#x02013;9.<pub-id pub-id-type="pmid">18302628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><collab>Collaborators GBDNSD</collab></person-group><article-title>Global, regional, and national burden of disorders affecting the nervous system, 1990&#x02013;2021: a systematic analysis for the Global Burden of Disease Study 2021</article-title><source>Lancet Neurol</source><year>2024</year><volume>23</volume><issue>4</issue><fpage>344</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">38493795</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Collaborators GBDNSD. Global, regional, and national burden of disorders affecting the nervous system, 1990&#x02013;2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344&#x02013;81.<pub-id pub-id-type="pmid">38493795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><collab>Collaborators GBDE</collab></person-group><article-title>Global, regional, and national burden of epilepsy, 1990&#x02013;2016: a systematic analysis for the Global Burden of Disease Study 2016</article-title><source>Lancet Neurol</source><year>2019</year><volume>18</volume><issue>4</issue><fpage>357</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">30773428</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Collaborators GBDE. Global, regional, and national burden of epilepsy, 1990&#x02013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):357&#x02013;75.<pub-id pub-id-type="pmid">30773428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ngugi</surname><given-names>AK</given-names></name><name><surname>Bottomley</surname><given-names>C</given-names></name><name><surname>Kleinschmidt</surname><given-names>I</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name><name><surname>Newton</surname><given-names>CR</given-names></name></person-group><article-title>Estimation of the burden of active and life-time epilepsy: a meta-analytic approach</article-title><source>Epilepsia</source><year>2010</year><volume>51</volume><issue>5</issue><fpage>883</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">20067507</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883&#x02013;90.<pub-id pub-id-type="pmid">20067507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Rudnicka</surname><given-names>E</given-names></name><name><surname>Napierala</surname><given-names>P</given-names></name><name><surname>Podfigurna</surname><given-names>A</given-names></name><name><surname>Meczekalski</surname><given-names>B</given-names></name><name><surname>Smolarczyk</surname><given-names>R</given-names></name><name><surname>Grymowicz</surname><given-names>M</given-names></name></person-group><article-title>The World Health Organization (WHO) approach to healthy ageing</article-title><source>Maturitas</source><year>2020</year><volume>139</volume><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">32747042</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Rudnicka E, Napierala P, Podfigurna A, Meczekalski B, Smolarczyk R, Grymowicz M. The World Health Organization (WHO) approach to healthy ageing. Maturitas. 2020;139:6&#x02013;11.<pub-id pub-id-type="pmid">32747042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>JB</given-names></name></person-group><article-title>Misleading presentation of epilepsy in elderly people</article-title><source>Age Ageing</source><year>1989</year><volume>18</volume><issue>1</issue><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">2469318</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Godfrey JB. Misleading presentation of epilepsy in elderly people. Age Ageing. 1989;18(1):17&#x02013;20.<pub-id pub-id-type="pmid">2469318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Stephen</surname><given-names>LJ</given-names></name><name><surname>Brodie</surname><given-names>MJ</given-names></name></person-group><article-title>Epilepsy in elderly people</article-title><source>Lancet</source><year>2000</year><volume>355</volume><issue>9213</issue><fpage>1441</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">10791538</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000;355(9213):1441&#x02013;6.<pub-id pub-id-type="pmid">10791538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>Jette</surname><given-names>N</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name></person-group><article-title>Epilepsy in older people</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10225</issue><fpage>735</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">32113502</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395(10225):735&#x02013;48.<pub-id pub-id-type="pmid">32113502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><collab>Collaborators GBDRF</collab></person-group><article-title>Global burden of 87 risk factors in 204 countries and territories, 1990&#x02013;2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10258</issue><fpage>1223</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">33069327</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Collaborators GBDRF. Global burden of 87 risk factors in 204 countries and territories, 1990&#x02013;2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223&#x02013;49.<pub-id pub-id-type="pmid">33069327</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><collab>Diseases GBD</collab><collab>Injuries C</collab></person-group><article-title>Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990&#x02013;2021: a systematic analysis for the Global Burden of Disease Study 2021</article-title><source>Lancet</source><year>2024</year><volume>403</volume><issue>10440</issue><fpage>2133</fpage><lpage>2161</lpage><pub-id pub-id-type="pmid">38642570</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Diseases GBD, Injuries C. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990&#x02013;2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133&#x02013;61.<pub-id pub-id-type="pmid">38642570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><collab>Collaborators GBDRF</collab></person-group><article-title>Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990&#x02013;2021: a systematic analysis for the Global Burden of Disease Study 2021</article-title><source>Lancet</source><year>2024</year><volume>403</volume><issue>10440</issue><fpage>2162</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">38762324</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Collaborators GBDRF. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990&#x02013;2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2162&#x02013;203.<pub-id pub-id-type="pmid">38762324</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><collab>Proposal for classification of epilepsies and epileptic syndromes</collab></person-group><article-title>Commission on classification and terminology of the international league against epilepsy</article-title><source>Epilepsia</source><year>1985</year><volume>26</volume><issue>3</issue><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">3924589</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Proposal for classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia. 1985;26(3):268&#x02013;78.<pub-id pub-id-type="pmid">3924589</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Er</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Ivers</surname><given-names>R</given-names></name><etal/></person-group><article-title>Burden of falls among people aged 60 years and older in mainland China, 1990&#x02013;2019: findings from the Global Burden of Disease Study 2019</article-title><source>Lancet Public Health</source><year>2021</year><volume>6</volume><issue>12</issue><fpage>e907</fpage><lpage>e918</lpage><pub-id pub-id-type="pmid">34838197</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ye P, Er Y, Wang H, Fang L, Li B, Ivers R, et al. Burden of falls among people aged 60 years and older in mainland China, 1990&#x02013;2019: findings from the Global Burden of Disease Study 2019. Lancet Public Health. 2021;6(12):e907&#x02013;18.<pub-id pub-id-type="pmid">34838197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Bian</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Global, regional, and national burden of HIV and other sexually transmitted infections in older adults aged 60&#x02013;89 years from 1990 to 2019: results from the Global Burden of Disease Study 2019</article-title><source>Lancet Healthy Longev</source><year>2024</year><volume>5</volume><issue>1</issue><fpage>e17</fpage><lpage>e30</lpage><pub-id pub-id-type="pmid">38183996</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Fu L, Tian T, Wang B, Lu Z, Bian J, Zhang W, et al. Global, regional, and national burden of HIV and other sexually transmitted infections in older adults aged 60&#x02013;89 years from 1990 to 2019: results from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2024;5(1):e17&#x02013;30.<pub-id pub-id-type="pmid">38183996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Rowan</surname><given-names>AJ</given-names></name><name><surname>Ramsay</surname><given-names>RE</given-names></name><name><surname>Collins</surname><given-names>JF</given-names></name><name><surname>Pryor</surname><given-names>F</given-names></name><name><surname>Boardman</surname><given-names>KD</given-names></name><name><surname>Uthman</surname><given-names>BM</given-names></name><etal/></person-group><article-title>New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>11</issue><fpage>1868</fpage><lpage>1873</lpage><pub-id pub-id-type="pmid">15955935</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64(11):1868&#x02013;73.<pub-id pub-id-type="pmid">15955935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>RE</given-names></name><name><surname>Uthman</surname><given-names>B</given-names></name><name><surname>Pryor</surname><given-names>FM</given-names></name><name><surname>Rowan</surname><given-names>AJ</given-names></name><name><surname>Bainbridge</surname><given-names>J</given-names></name><name><surname>Spitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study</article-title><source>Epilepsia</source><year>2008</year><volume>49</volume><issue>7</issue><fpage>1180</fpage><lpage>1185</lpage><pub-id pub-id-type="pmid">18494791</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ramsay RE, Uthman B, Pryor FM, Rowan AJ, Bainbridge J, Spitz M, et al. Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia. 2008;49(7):1180&#x02013;5.<pub-id pub-id-type="pmid">18494791</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Werhahn</surname><given-names>KJ</given-names></name><name><surname>Trinka</surname><given-names>E</given-names></name><name><surname>Dobesberger</surname><given-names>J</given-names></name><name><surname>Unterberger</surname><given-names>I</given-names></name><name><surname>Baum</surname><given-names>P</given-names></name><name><surname>Deckert-Schmitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy</article-title><source>Epilepsia</source><year>2015</year><volume>56</volume><issue>3</issue><fpage>450</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">25684224</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56(3):450&#x02013;9.<pub-id pub-id-type="pmid">25684224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Rezaei</surname><given-names>F</given-names></name><name><surname>Mazidimoradi</surname><given-names>A</given-names></name><name><surname>Rayatinejad</surname><given-names>A</given-names></name><name><surname>Allahqoli</surname><given-names>L</given-names></name><name><surname>Salehiniya</surname><given-names>H</given-names></name></person-group><article-title>Temporal trends of tracheal, bronchus, and lung cancer between 2010 and 2019, in Asian countries by geographical region and sociodemographic index, comparison with global data</article-title><source>Thorac Cancer</source><year>2023</year><volume>14</volume><issue>18</issue><fpage>1668</fpage><lpage>1706</lpage><pub-id pub-id-type="pmid">37127553</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Rezaei F, Mazidimoradi A, Rayatinejad A, Allahqoli L, Salehiniya H. Temporal trends of tracheal, bronchus, and lung cancer between 2010 and 2019, in Asian countries by geographical region and sociodemographic index, comparison with global data. Thorac Cancer. 2023;14(18):1668&#x02013;706.<pub-id pub-id-type="pmid">37127553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Global, regional, and national burden of inguinal, femoral, and abdominal hernias: a systematic analysis of prevalence, incidence, deaths, and DALYs with projections to 2030</article-title><source>Int J Surg</source><year>2024</year><volume>110</volume><issue>4</issue><fpage>1951</fpage><lpage>1967</lpage><pub-id pub-id-type="pmid">38265437</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wang F, Ma B, Ma Q, Liu X. Global, regional, and national burden of inguinal, femoral, and abdominal hernias: a systematic analysis of prevalence, incidence, deaths, and DALYs with projections to 2030. Int J Surg. 2024;110(4):1951&#x02013;67.<pub-id pub-id-type="pmid">38265437</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>ZJ</given-names></name></person-group><article-title>Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China</article-title><source>Public Health</source><year>2019</year><volume>172</volume><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">31220754</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Liu X, Yu C, Bi Y, Zhang ZJ. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health. 2019;172:70&#x02013;80.<pub-id pub-id-type="pmid">31220754</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>TC</given-names></name><name><surname>Yin</surname><given-names>XL</given-names></name><name><surname>Man</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>XR</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name></person-group><article-title>Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019</article-title><source>Br J Dermatol</source><year>2022</year><volume>186</volume><issue>4</issue><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">34758111</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Chen H, Zhang TC, Yin XL, Man JY, Yang XR, Lu M. Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019. Br J Dermatol. 2022;186(4):673&#x02013;83.<pub-id pub-id-type="pmid">34758111</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Ordunez</surname><given-names>P</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Soliz</surname><given-names>P</given-names></name><name><surname>Giraldo</surname><given-names>G</given-names></name><name><surname>Mujica</surname><given-names>OJ</given-names></name><name><surname>Nordet</surname><given-names>P</given-names></name></person-group><article-title>Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990&#x02013;2017: a population-based study</article-title><source>Lancet Glob Health</source><year>2019</year><volume>7</volume><issue>10</issue><fpage>e1388</fpage><lpage>e1397</lpage><pub-id pub-id-type="pmid">31537369</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ordunez P, Martinez R, Soliz P, Giraldo G, Mujica OJ, Nordet P. Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990&#x02013;2017: a population-based study. Lancet Glob Health. 2019;7(10):e1388&#x02013;97.<pub-id pub-id-type="pmid">31537369</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Knoll</surname><given-names>M</given-names></name><name><surname>Furkel</surname><given-names>J</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Abdollahi</surname><given-names>A</given-names></name><name><surname>Karch</surname><given-names>A</given-names></name><name><surname>Stock</surname><given-names>C</given-names></name></person-group><article-title>An R package for an integrated evaluation of statistical approaches to cancer incidence projection</article-title><source>BMC Med Res Methodol</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>257</fpage><pub-id pub-id-type="pmid">33059585</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Knoll M, Furkel J, Debus J, Abdollahi A, Karch A, Stock C. An R package for an integrated evaluation of statistical approaches to cancer incidence projection. BMC Med Res Methodol. 2020;20(1):257.<pub-id pub-id-type="pmid">33059585</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Beghi</surname><given-names>E</given-names></name><name><surname>Giussani</surname><given-names>G</given-names></name></person-group><article-title>Aging and the epidemiology of epilepsy</article-title><source>Neuroepidemiology</source><year>2018</year><volume>51</volume><issue>3&#x02013;4</issue><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">30253417</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Beghi E, Giussani G. Aging and the epidemiology of epilepsy. Neuroepidemiology. 2018;51(3&#x02013;4):216&#x02013;23.<pub-id pub-id-type="pmid">30253417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Trinka</surname><given-names>E</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Dash</surname><given-names>A</given-names></name></person-group><article-title>Epilepsy in Asia: Disease burden, management barriers, and challenges</article-title><source>Epilepsia</source><year>2019</year><volume>60</volume><issue>Suppl 1</issue><fpage>7</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">29953579</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Trinka E, Kwan P, Lee B, Dash A. Epilepsy in Asia: Disease burden, management barriers, and challenges. Epilepsia. 2019;60(Suppl 1):7&#x02013;21.<pub-id pub-id-type="pmid">29953579</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Brodie</surname><given-names>MJ</given-names></name><name><surname>Elder</surname><given-names>AT</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name></person-group><article-title>Epilepsy in later life</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>11</issue><fpage>1019</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">19800848</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019&#x02013;30.<pub-id pub-id-type="pmid">19800848</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Trinka</surname><given-names>E</given-names></name></person-group><article-title>Epilepsy: comorbidity in the elderly</article-title><source>Acta Neurol Scand Suppl</source><year>2003</year><volume>180</volume><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">14510818</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Trinka E. Epilepsy: comorbidity in the elderly. Acta Neurol Scand Suppl. 2003;180:33&#x02013;6.<pub-id pub-id-type="pmid">14510818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>G</given-names></name><name><surname>Mrengqwa</surname><given-names>L</given-names></name><name><surname>Geffen</surname><given-names>L</given-names></name></person-group><article-title>"They don't care about us": older people's experiences of primary healthcare in Cape Town, South Africa</article-title><source>BMC Geriatr</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>98</fpage><pub-id pub-id-type="pmid">30947709</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kelly G, Mrengqwa L, Geffen L. &#x0201c;They don&#x02019;t care about us&#x0201d;: older people&#x02019;s experiences of primary healthcare in Cape Town, South Africa. BMC Geriatr. 2019;19(1):98.<pub-id pub-id-type="pmid">30947709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Fiest</surname><given-names>KM</given-names></name><name><surname>Sauro</surname><given-names>KM</given-names></name><name><surname>Wiebe</surname><given-names>S</given-names></name><name><surname>Patten</surname><given-names>SB</given-names></name><name><surname>Kwon</surname><given-names>CS</given-names></name><name><surname>Dykeman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies</article-title><source>Neurology</source><year>2017</year><volume>88</volume><issue>3</issue><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">27986877</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296&#x02013;303.<pub-id pub-id-type="pmid">27986877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>J</given-names></name><name><surname>Kjeldsen</surname><given-names>MJ</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Friis</surname><given-names>ML</given-names></name><name><surname>Sidenius</surname><given-names>P</given-names></name></person-group><article-title>Gender differences in epilepsy</article-title><source>Epilepsia</source><year>2005</year><volume>46</volume><issue>6</issue><fpage>956</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">15946339</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia. 2005;46(6):956&#x02013;60.<pub-id pub-id-type="pmid">15946339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>DS</given-names></name></person-group><article-title>The neuroendocrine basis of sex differences in epilepsy</article-title><source>Pharmacol Biochem Behav</source><year>2017</year><volume>152</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">27424276</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Reddy DS. The neuroendocrine basis of sex differences in epilepsy. Pharmacol Biochem Behav. 2017;152:97&#x02013;104.<pub-id pub-id-type="pmid">27424276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Tomson</surname><given-names>T</given-names></name><name><surname>Surges</surname><given-names>R</given-names></name><name><surname>Delamont</surname><given-names>R</given-names></name><name><surname>Haywood</surname><given-names>S</given-names></name><name><surname>Hesdorffer</surname><given-names>DC</given-names></name></person-group><article-title>Who to target in sudden unexpected death in epilepsy prevention and how? Risk factors, biomarkers, and intervention study designs</article-title><source>Epilepsia</source><year>2016</year><volume>57</volume><issue>Suppl 1</issue><fpage>4</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">26749012</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Tomson T, Surges R, Delamont R, Haywood S, Hesdorffer DC. Who to target in sudden unexpected death in epilepsy prevention and how? Risk factors, biomarkers, and intervention study designs. Epilepsia. 2016;57(Suppl 1):4&#x02013;16.<pub-id pub-id-type="pmid">26749012</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Sveinsson</surname><given-names>O</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>Mattsson</surname><given-names>P</given-names></name><name><surname>Carlsson</surname><given-names>S</given-names></name><name><surname>Tomson</surname><given-names>T</given-names></name></person-group><article-title>Clinical risk factors in SUDEP: A nationwide population-based case-control study</article-title><source>Neurology</source><year>2020</year><volume>94</volume><issue>4</issue><fpage>e419</fpage><lpage>e429</lpage><pub-id pub-id-type="pmid">31831600</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Sveinsson O, Andersson T, Mattsson P, Carlsson S, Tomson T. Clinical risk factors in SUDEP: A nationwide population-based case-control study. Neurology. 2020;94(4):e419&#x02013;29.<pub-id pub-id-type="pmid">31831600</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>PN</given-names></name><name><surname>Filippi</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>HW</given-names></name></person-group><article-title>The descriptive epidemiology of epilepsy-a review</article-title><source>Epilepsy Res</source><year>2009</year><volume>85</volume><issue>1</issue><fpage>31</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">19369037</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Banerjee PN, Filippi D, Allen HW. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009;85(1):31&#x02013;45.<pub-id pub-id-type="pmid">19369037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Bharucha</surname><given-names>NE</given-names></name><name><surname>Bharucha</surname><given-names>EP</given-names></name><name><surname>Bharucha</surname><given-names>AE</given-names></name><name><surname>Bhise</surname><given-names>AV</given-names></name><name><surname>Schoenberg</surname><given-names>BS</given-names></name></person-group><article-title>Prevalence of epilepsy in the Parsi community of Bombay</article-title><source>Epilepsia</source><year>1988</year><volume>29</volume><issue>2</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">3258234</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Bharucha NE, Bharucha EP, Bharucha AE, Bhise AV, Schoenberg BS. Prevalence of epilepsy in the Parsi community of Bombay. Epilepsia. 1988;29(2):111&#x02013;5.<pub-id pub-id-type="pmid">3258234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Shan</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gender and Socioeconomic Disparities in Global Burden of Epilepsy: An Analysis of Time Trends From 1990 to 2017</article-title><source>Front Neurol</source><year>2021</year><volume>12</volume><fpage>643450</fpage><pub-id pub-id-type="pmid">33935942</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hu Y, Shan Y, Du Q, Ding Y, Shen C, Wang S, et al. Gender and Socioeconomic Disparities in Global Burden of Epilepsy: An Analysis of Time Trends From 1990 to 2017. Front Neurol. 2021;12:643450.<pub-id pub-id-type="pmid">33935942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Kong</surname><given-names>XM</given-names></name><name><surname>Lv</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Yang</surname><given-names>XT</given-names></name><etal/></person-group><article-title>Analysis of the global burden of disease study highlights the global, regional, and national trends of idiopathic epilepsy epidemiology from 1990 to 2019</article-title><source>Prev Med Rep</source><year>2023</year><volume>36</volume><fpage>102522</fpage><pub-id pub-id-type="pmid">38116287</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Zhang YJ, Kong XM, Lv JJ, Yang CH, Li XY, Yang XT, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of idiopathic epilepsy epidemiology from 1990 to 2019. Prev Med Rep. 2023;36:102522.<pub-id pub-id-type="pmid">38116287</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Eum</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Koyanagi</surname><given-names>A</given-names></name><name><surname>Jacob</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><etal/></person-group><article-title>Burden of neurological diseases in Asia from 1990 to 2019: a systematic analysis using the Global Burden of Disease Study data</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><issue>9</issue><fpage>e059548</fpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Kang S, Eum S, Chang Y, Koyanagi A, Jacob L, Smith L, et al. Burden of neurological diseases in Asia from 1990 to 2019: a systematic analysis using the Global Burden of Disease Study data. BMJ Open. 2022;12(9):e059548.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Berkovic</surname><given-names>S</given-names></name><name><surname>Capovilla</surname><given-names>G</given-names></name><name><surname>Connolly</surname><given-names>MB</given-names></name><name><surname>French</surname><given-names>J</given-names></name><name><surname>Guilhoto</surname><given-names>L</given-names></name><etal/></person-group><article-title>ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology</article-title><source>Epilepsia</source><year>2017</year><volume>58</volume><issue>4</issue><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">28276062</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512&#x02013;21.<pub-id pub-id-type="pmid">28276062</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>